Immutep Ltd ADR (IMMP)

$1.80 +0.02 (1.12%)
Market Cap 262.00M
Revenue (ttm) 6.69M
Net Income (ttm) -39.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -594.62%
Debt to Equity Ratio 0.01
Volume 59,800
Avg Vol 156,388
Day's Range N/A - N/A
Shares Out 147.19M
Stochastic %K 32%
Beta 1.92
Analysts Strong Sell
Price Target $9.50

Company Profile

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 2 8315 7003
Fax: 61 2 8569 1880
Address:
Australia Square, Level 32 264 George Street, Sydney, Australia
bylocehi
bylocehi Dec. 5 at 3:31 PM
$IMMP Using the equivalent of 180,000 adr shares for a bonus is smart Converses cash. Buyout beomes inexorable once readouts point to approval of eftilagimod which could occur in 2026! Bonus stock is minuscule compared to short positions. Shorts paying several times this in interest!!!! Suspect interest on short shares will increase faster than share price
0 · Reply
rispi
rispi Dec. 5 at 9:11 AM
$IMMP are they paying employees with free shares, lots of shares? plenty of shares, 1,800,968 on ASX
0 · Reply
theinvestaar
theinvestaar Dec. 5 at 2:07 AM
$IMMP Come on Marc!!!!
0 · Reply
bylocehi
bylocehi Dec. 4 at 8:14 PM
$IMMP Since Merck is running tacti004 study they will have access to the results earlier than anybody else. Suspect Merck will announce combination therapy with subcutaneous Keytruda with Eftilagimod as soon as they are convinced of a positive outcome. This could occur as early as 2026 and shorts need to come up with an exit stategy before an inexorable price increase costing them millions
2 · Reply
NOCKNOCK
NOCKNOCK Dec. 4 at 6:14 PM
$IMMP
0 · Reply
ckruel
ckruel Dec. 4 at 3:40 PM
$IMMP the call for 2026 is to shift investing into health care, a sector that has been beaten down, as other sectors may suffer in a bearish 2026 market, finally we may see some positive movement in the bio sector.
0 · Reply
NOCKNOCK
NOCKNOCK Dec. 4 at 12:33 AM
$IMMP
0 · Reply
Messerschmittbf109
Messerschmittbf109 Dec. 3 at 9:02 PM
$IMMP a disaster
0 · Reply
Messerschmittbf109
Messerschmittbf109 Dec. 3 at 9:01 PM
$IMMP need cash
0 · Reply
bylocehi
bylocehi Dec. 3 at 6:59 PM
$IMMP Don’t think we will see price dilution at current levels, maybe after share price increases after futility analysis indicates approval study is headed for completion in 2027
0 · Reply
Latest News on IMMP
Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

Oct 20, 2025, 8:01 AM EDT - 6 weeks ago

Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

Sep 8, 2025, 8:00 AM EDT - 3 months ago

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

Immutep Quarterly Activities Report Q4 FY25

Jul 30, 2025, 8:00 AM EDT - 4 months ago

Immutep Quarterly Activities Report Q4 FY25

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

Jul 29, 2025, 8:00 AM EDT - 4 months ago

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

May 27, 2025, 8:00 AM EDT - 6 months ago

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo

May 15, 2025, 3:50 PM EDT - 7 months ago

Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo

Immutep Limited: Surging On Positive Head And Neck Data

May 8, 2025, 8:46 AM EDT - 7 months ago

Immutep Limited: Surging On Positive Head And Neck Data

Immutep to Participate in Upcoming Investor Conferences

Apr 2, 2025, 8:00 AM EDT - 8 months ago

Immutep to Participate in Upcoming Investor Conferences

Immutep Quarterly Activities Report Q2 FY25

Jan 31, 2025, 8:00 AM EST - 11 months ago

Immutep Quarterly Activities Report Q2 FY25

Immutep Limited: Continuing To Make The Case For Eftilagimod

Jan 28, 2025, 4:37 PM EST - 11 months ago

Immutep Limited: Continuing To Make The Case For Eftilagimod

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Dec 17, 2024, 8:00 AM EST - 1 year ago

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Dec 12, 2024, 8:15 AM EST - 1 year ago

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Nov 15, 2024, 3:18 PM EST - 1 year ago

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

Nov 14, 2024, 11:16 AM EST - 1 year ago

Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Nov 14, 2024, 8:15 AM EST - 1 year ago

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Immutep Quarterly Activities Report Q1 FY25

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q1 FY25

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 10, 2024, 8:00 AM EDT - 1 year ago

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Immutep: Navigating The Bumps In The Road

Oct 7, 2024, 9:10 AM EDT - 1 year ago

Immutep: Navigating The Bumps In The Road

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

Sep 16, 2024, 8:00 AM EDT - 1 year ago

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

Immutep Quarterly Activities Report Q4 FY24

Jul 31, 2024, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q4 FY24

Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs

Jul 15, 2024, 1:54 PM EDT - 1 year ago

Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Jul 11, 2024, 6:40 PM EDT - 1 year ago

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Jul 3, 2024, 8:00 AM EDT - 1 year ago

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Immutep successfully completes institutional placement and institutional component of entitlement offer

Jun 5, 2024, 6:00 AM EDT - 1 year ago

Immutep successfully completes institutional placement and institutional component of entitlement offer

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Jun 2, 2024, 8:38 PM EDT - 1 year ago

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

May 15, 2024, 8:00 AM EDT - 1 year ago

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

May 2, 2024, 8:00 AM EDT - 1 year ago

Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Immutep: Realizing The Expected Catalysts, With More To Come

May 1, 2024, 12:39 PM EDT - 1 year ago

Immutep: Realizing The Expected Catalysts, With More To Come

Immutep Quarterly Activities Report Q3 FY24

Apr 29, 2024, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q3 FY24

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Apr 24, 2024, 8:00 AM EDT - 1 year ago

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Apr 18, 2024, 8:00 AM EDT - 1 year ago

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Apr 17, 2024, 8:00 AM EDT - 1 year ago

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Mar 5, 2024, 8:00 AM EST - 1 year ago

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Immutep Quarterly Activities Report Q2 FY24

Jan 30, 2024, 8:00 AM EST - 2 years ago

Immutep Quarterly Activities Report Q2 FY24

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Jan 4, 2024, 8:00 AM EST - 2 years ago

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Immutep: Upcoming Signals For 2024 (Maintain Buy)

Jan 3, 2024, 5:04 PM EST - 2 years ago

Immutep: Upcoming Signals For 2024 (Maintain Buy)

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Dec 21, 2023, 8:00 AM EST - 2 years ago

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Dec 7, 2023, 8:00 AM EST - 2 years ago

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Nov 22, 2023, 8:00 AM EST - 2 years ago

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Nov 9, 2023, 8:00 AM EST - 2 years ago

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

Nov 6, 2023, 8:00 AM EST - 2 years ago

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

Nov 3, 2023, 12:00 PM EDT - 2 years ago

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

Immutep to Participate in November Investor Events

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Immutep to Participate in November Investor Events

Immutep Quarterly Activities Report Q1 FY24

Oct 31, 2023, 8:00 AM EDT - 2 years ago

Immutep Quarterly Activities Report Q1 FY24

Immutep receives ~A$1.13 million R&D Tax Incentive

Oct 25, 2023, 8:00 AM EDT - 2 years ago

Immutep receives ~A$1.13 million R&D Tax Incentive

Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023

Oct 24, 2023, 8:00 AM EDT - 2 years ago

Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023

Immutep's Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Immutep's Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer

Immutep Announces Publication of Abstracts at ESMO Congress 2023

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Immutep Announces Publication of Abstracts at ESMO Congress 2023

Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Oct 3, 2023, 8:00 AM EDT - 2 years ago

Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

bylocehi
bylocehi Dec. 5 at 3:31 PM
$IMMP Using the equivalent of 180,000 adr shares for a bonus is smart Converses cash. Buyout beomes inexorable once readouts point to approval of eftilagimod which could occur in 2026! Bonus stock is minuscule compared to short positions. Shorts paying several times this in interest!!!! Suspect interest on short shares will increase faster than share price
0 · Reply
rispi
rispi Dec. 5 at 9:11 AM
$IMMP are they paying employees with free shares, lots of shares? plenty of shares, 1,800,968 on ASX
0 · Reply
theinvestaar
theinvestaar Dec. 5 at 2:07 AM
$IMMP Come on Marc!!!!
0 · Reply
bylocehi
bylocehi Dec. 4 at 8:14 PM
$IMMP Since Merck is running tacti004 study they will have access to the results earlier than anybody else. Suspect Merck will announce combination therapy with subcutaneous Keytruda with Eftilagimod as soon as they are convinced of a positive outcome. This could occur as early as 2026 and shorts need to come up with an exit stategy before an inexorable price increase costing them millions
2 · Reply
NOCKNOCK
NOCKNOCK Dec. 4 at 6:14 PM
$IMMP
0 · Reply
ckruel
ckruel Dec. 4 at 3:40 PM
$IMMP the call for 2026 is to shift investing into health care, a sector that has been beaten down, as other sectors may suffer in a bearish 2026 market, finally we may see some positive movement in the bio sector.
0 · Reply
NOCKNOCK
NOCKNOCK Dec. 4 at 12:33 AM
$IMMP
0 · Reply
Messerschmittbf109
Messerschmittbf109 Dec. 3 at 9:02 PM
$IMMP a disaster
0 · Reply
Messerschmittbf109
Messerschmittbf109 Dec. 3 at 9:01 PM
$IMMP need cash
0 · Reply
bylocehi
bylocehi Dec. 3 at 6:59 PM
$IMMP Don’t think we will see price dilution at current levels, maybe after share price increases after futility analysis indicates approval study is headed for completion in 2027
0 · Reply
Harryhakbijl
Harryhakbijl Dec. 3 at 5:46 PM
$IMMP has to be fear of dilution. All these potential diamonds that need funds to progress
0 · Reply
NOCKNOCK
NOCKNOCK Dec. 3 at 3:02 PM
$IMMP when opportunity knocks! Frustration and plenty
0 · Reply
NOCKNOCK
NOCKNOCK Dec. 3 at 2:57 PM
$IMMP rats scurrying in the tsx
0 · Reply
Geauxtigers47
Geauxtigers47 Dec. 3 at 2:51 PM
$IMMP wtf 🤬
0 · Reply
SeatownGreen
SeatownGreen Dec. 3 at 2:49 PM
$IMMP The only logical explanation is Immutep communicating like we see to the market doing fake staged interviews and something different to institutional investors. There is a massive disconnect that should be investigated.
0 · Reply
tokar
tokar Dec. 3 at 2:38 PM
$IMMP most disappointing stock
0 · Reply
Bruyne
Bruyne Dec. 3 at 6:05 AM
$IMMP oh boy, ASX again -9%…
0 · Reply
LAG3boom
LAG3boom Dec. 3 at 4:18 AM
$IMMP Amigos…… I believe. Get that cheese!
0 · Reply
brad97
brad97 Dec. 3 at 3:44 AM
$IMMP Tedious. Very tedious.
0 · Reply
Tulipsdulips
Tulipsdulips Dec. 3 at 2:34 AM
$IMMP https://youtu.be/rbG7B0Oti5A?si=H3avDWUofXxDA_Y8
0 · Reply
NOCKNOCK
NOCKNOCK Dec. 2 at 8:58 PM
$IMMP yes I bought more...
0 · Reply
theinvestaar
theinvestaar Dec. 2 at 8:29 PM
$IMMP Why lower??
0 · Reply